UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10–Q

(Mark One)

For the quarterly period ended SeptemberJune 30, 20172018

For the transition period from _________ to ________

Commission file numbers 000–32141

NUTRA PHARMA CORP.

(Name of registrant as specified in its charter)

(954) 509–0911

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yesþ No¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S–T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yesþ No¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non–accelerated filer, or a smaller reporting company, or an emerging growth company.

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.  o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes¨ Noþ

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of November 20, 2017,August 14, 2018, there was 1,863,417,5683,637,448,131 shares of common stock.

TABLE OF CONTENTS

i

NUTRA PHARMA CORP.

Nutra Pharma Corp. is referred to hereinafter as “we”, “us” or “our”

Forward Looking Statements

This Quarterly Report on Form 10-Q10–Q for the period ending SeptemberJune 30, 2017,2018, contains forward-lookingforward–looking statements that involve risks and uncertainties, as well as assumptions that if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-lookingforward–looking statements. The words or phrases “would be,” “will allow, “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking“forward–looking statements.” We are subject to risks detailed in Item 1(a). All statements other than statements of historical fact are statements that could be deemed forward-lookingforward–looking statements, including: (a) any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; and (b) any statements of the plans, strategies and objectives of management for future operations; and (c) any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward-lookingforward–looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

3

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

NUTRA PHARMA CORP.

Condensed Consolidated Balance Sheets

See the accompanying notes to the unaudited condensed consolidated financial statements

4

NUTRA PHARMA CORP.

Condensed Consolidated Statements of Operations  

(Unaudited)

See the accompanying notes to the unaudited condensed consolidated financial statements

5

NUTRA PHARMA CORP.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

See the accompanying notes to the unaudited condensed consolidated financial statements

6

NUTRA PHARMA CORP.

Notes to Unaudited Condensed Consolidated Financial Statements

SeptemberJune 30, 20172018

1.     BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.Exotic–Bird.com.

Through its wholly-ownedwholly–owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin^®, an over-the-counterover–the–counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin^®, an over-the-counterover–the–counter pain reliever that is a stronger version of Cobroxin^® and is designed to treat severe chronic pain. In December 2014, we launched Pet Pain-Away,Pain–Away, an over-the-counterover–the–counter pain reliever designed to treat pain in cats and dogs.

Basis of Presentation and Consolidation

The Unaudited Condensed Consolidated Financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K10–K for the year ended December 31, 2016.2017. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial statements should be read in conjunction with the Condensed Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K.10–K.

The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-ownedwholly–owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

Liquidity and Going Concern

Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $56,396,223$62,826,493 at SeptemberJune 30, 2017.2018. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $5,067,722$5,133,097 and a stockholders’ deficit of $5,042,956$5,104,837 at SeptemberJune 30, 2017.2018.  

There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.

At SeptemberJune 30, 2017,2018, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.

The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Use of Estimates

The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the

7

financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-livedlong–lived assets, and the valuation of stock-basedstock–based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.

Revenue Recognition

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.

We collect 100% of the cash proceeds from the sale of product by our distributor and remit a portion of the cash proceeds received back to the distributor.  We record product sales on a netgross basis.

Adoption of ASC 606, Revenue from Contracts with Customers

On January 1, 2018, we adopted ASC 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic revenue recognition methodology under ASC 605, Revenue Recognition.

The cumulative impact of adopting ASC 606 resulted in no changes to retained earnings at January 1, 2018. The impact to revenue for the six months ended June 30, 2018 was an increase of $2,780 as a result of applying ASC 606 to certain revenues generated through online distributors which are now presented gross as we have control over providing the products related to such revenues.

For the six months ended June 30, 2018, the revenue recognized from contracts with customers was $60,357. The impact of adoption of ASC 606 on our unaudited condensed consolidated statement of operations was as follows:

There was no balance sheet impact.

Accounting for Shipping and Handling Costs

We record shipping and handling costs incurred in cost of sales.

Cash and Cash Equivalents

We consider all highly liquid investments with an original maturity of three-monthsthree–months or less to be cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts

We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable.

Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.

Inventories

Inventories, which are stated at the lower of average cost or market, and consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand.  If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downsWrite–downs are charged to cost of goods sold. Our inventory is carried net of a valuation allowance of $30,805$30,885 at SeptemberJune 30, 20172018 and December 31, 2016.2017.

Financial Instruments and Concentration of Credit Risk

Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.

Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three-monthssix months ended SeptemberJune 30, 2017,2018, there were two customerswas one customer that accounted for 17% and 46%45% of the total revenues, respectively. For the nine-months ended September 30, 2017, there were three customers that accounted for 14%, 14% and 28% of the total revenues, respectively.revenues.

Derivative Financial Instruments

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and

8

is then re-valuedre–valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-basedoption–based simple derivative financial instruments, the Company uses the Black-Scholes option-pricingBlack–Scholes option–pricing model to value the derivative instruments at inception and subsequent valuation dates. For embedded derivatives, the Company uses a Dilution-Adjusted Black-ScholesDilution–Adjusted Black–Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessedre–assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-currentnon–current based on whether or not net-cashnet–cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.

Convertible Debt

We bifurcate the embedded derivative element in convertible debt which contain conversion features which are not considered to be conventional convertible debt.  The convertible debt is recorded at the bifurcated amount after reducing the proceeds for the liability related to the embedded call provision which is accounted for separately in the accompanying balance sheets.  After recording the initial amount of the debt, the discount related to the bifurcated embedded derivative is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.  

The Fair Value Measurement Option

We have elected the fair value measurement option, and record the entire hybrid financing instrument at fair value under the guidance of SFAS155.

Property and Equipment and Long-LivedLong–Lived Assets

Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-linestraight–line method over the estimated useful lives of the assets of 3 – 7 years.

Property and equipment consists of the following at SeptemberJune 30, 20172018 and December 31, 2016:2017:

We review our long-livedlong–lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At SeptemberJune 30, 2017,2018, we believe the carrying values of our long-livedlong–lived assets are recoverable. Depreciation expense for the nine-monthssix–months ended SeptemberJune 30, 2018 and 2017 was $3,753 and 2016 was $4,421 and $6,421,$3,253, respectively, and $1,168$1,825 and $2,157$1,379 for the three-monthsthree–months ended SeptemberJune 30, 20172018 and 2016, respectively.

Advertising

All advertising costs are expensed as incurred.  Advertising costs were approximately $400 and $2,459 for the three-months ended September 30, 2017, and 2016, respectively. Advertising costs were approximately $2,015 and $2,834 for the nine-months ended September 30, 2017 and 2016, respectively.

Income Taxes

We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740,Income Taxes(“ASC Topic 740”). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.

On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position.  At SeptemberJune 30, 2017,2018, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.

9

Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate. The Company’s 20132015 to 20162017 tax returns are subject to examination by Internal Revenue Services and State Taxing Agencies.

Stock-BasedStock–Based Compensation

We account for stock-basedstock–based compensation in accordance with FASB ASC Topic 718,Stock Compensation(ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-basedshare–based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-basedshare–based payment arrangements and requires all entities to apply a fair-value-basedfair–value–based measurement in accounting for share-basedshare–based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employeesnon–employees in share-basedshare–based payment transactions.

Net Loss Per Share

Net loss per share is calculated in accordance with ASC Topic 260,Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutiveanti��dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares. As of SeptemberJune 30, 20172018 and 2016,2017, the following items were not included in dilutive loss as the effect is anti-dilutive:anti–dilutive:

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02,2016–02,Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-useright–of–use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-022016–02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We expect the impact of this ASU will result in the recognition of right-of-useright–of–use assets and related obligations.

In March 2016, the FASB issued Accounting Standards Update 2016-08 Revenue from Contracts with Customers (Topic 606) to clarify implementation guidance on principal versus agent considerations (for reporting revenue on a gross or net basis). The ASU is an amendment to Topic 606, clarifies the implementation guidance, and requires an entity to account for revenue as an agent when another entity controls the specified good or service before that good or service is transferred to the customer. This ASU is effective for annual periods beginning after December 15, 2017. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our net presentation of revenue. 

In April 2016, the FASB issued ASU 2016–10 Revenue from Contract with Customers (Topic 606): identifying Performance Obligations and Licensing “The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments in this Update are intended render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.

All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

10

2.     FAIR VALUE MEASUREMENTS

Certain assets and liabilities that are measured at fair value on a recurring basis at SeptemberJune 30, 20172018 are measured in accordance with FASB ASC Topic 820-10-05,820–10–05,Fair Value Measurements. FASB ASC Topic 820-10-05820–10–05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financialnon–financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.

The statement requires fair value measurement be classified and disclosed in one of the following three categories:

The following table summarizes our financial instruments measured at fair value at SeptemberJune 30, 20172018 and December 31, 2016:2017:

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the nine-monthssix months ended SeptemberJune 30, 2018 and the year ended December 31, 2017:

(1)   The gain related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying condensed consolidated unaudited statement of operations.

The Company values itsWe valued our warrants using a Dilution-Adjusted Black-ScholesDilution–Adjusted Black–Scholes Model.  Assumptions used include (1) 0.26% to 1.93% risk-freerisk–free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 196%-211%–267% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted.

The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value at SeptemberJune 30, 2018 and December 31, 2017:

11

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the nine-monthssix months ended SeptemberJune 30, 2018 and the year ended December 31, 2017 for the Convertible Notes:

3.     INVENTORIES

Inventories are valued at the lower of cost or market on an average cost basis. At SeptemberJune 30, 20172018 and December 31, 2016,2017, inventories were as follows:

4.     DUE TOFROM OFFICERS

At SeptemberJune 30, 2017 and December 31, 2016,2018, the balance due tofrom our officer, Mr. Deitsch, and Companies owned by him is $193,359 and $52,025, respectively. The loan is an unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%.was $267,192. During the nine-monthssix months ended SeptemberJune 30, 2017,2018, we borrowed $302,350advanced $106,150 to and repaid $174,400 to Mr. Deitschcollected $105,100 from him and the Companies owned by him. During the year ended December 31, 2016, we borrowed $314,951 and repaid $319,675 to Mr. Deitsch and the Companies owned by him. In addition, Mr. Deitsch accepted a total of 15,000,000 shares of the Company's restricted common stock as a repayment to discharge $100,000 of his outstanding loan in June 2016.

5.     OTHER DEBTINDEBTEDNESS

Other debt (Both short-term and long term)indebtedness consists of the following at SeptemberJune 30, 20172018 and December 31, 2016:2017:

(1)

During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by our President and CEO, Rik Deitsch. We repaid principal balance in full as of December 31, 2016. During the nine-months ended SeptemberAt June 30, 2017, we made the payment of $20,000 of the accrued interest. At September 30, 2017,2018, we owed this director accrued interest of $132,264.$133,647, which is included in accrued expenses in the condensed consolidated balance sheets.

In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to one of our directors’ owned Companies. The notes carry interest at 12% annually and are due on the date that is nine-monthsnine–months from the execution and funding of the note. During March 2017, we repaid principal balance of $6,365. The loan is in default and negotiation for settlement. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365.  During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and iswas due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan is in default and negotiation for settlement. The loan was reclassified to notes payable – unrelated third parties after the director was resigned in March 2018. At SeptemberJune 30, 2017,2018, we owed this directorprincipal balance of $192,974 withand accrued interest of $11,038.$28,358.

12In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note is due in twelve months from the execution and funding of the note. At June 30, 2018, the principal balance of the loan net of discount is $11,000.

(2)

At SeptemberJune 30, 2017,2018, the balance of $1,097,537$1,550,567 net of discount of $16,494, consisted of the following loans:

·

On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment)non–payment). We repaid $25,000 during the six months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000).  The $100,000 defaultpenalty was expensed during 2012.  LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to us.

·

At SeptemberJune 30, 2017,2018, we owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to us.

·

In April 2016, we issued a promissory note to a non-relatedan unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note iswas due in one year from the execution and funding of the note. The loan is in default and negotiation of settlement. At SeptemberJune 30, 2017,2018, the accrued interest is $1,465.

$2,228.

·

In May 2016, wethe Company issued a promissory note to a non-relatedan unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The shares were valued at $0.0050 per share.loan is in default and in negotiation of settlement. At SeptemberJune 30, 2017,2018, the accrued interest is $22,500.$31,667.

·

In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The loan is in default and negotiation of settlement. At June 30, 2018, the accrued interest is $24,867.

·

In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the Notes with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and is due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our common stock (See Note 6). We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid–in capital. Amortization for the debt discount for the six months ended June 30, 2018 was $2,765. The loan is in default and negotiation of settlement. At June 30, 2018, the accrued interest is $31,239.

·

On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The loan is in default and in negotiation of settlement.

At June 30, 2018, the accrued interest is $13,438.

·

In JuneOctober 2016, we issued a promissory note to a non-relatedan unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The loan is in default and in negotiation of settlement. At SeptemberJune 30, 2017,2018, the accrued interest is $15,700.$21,167.

·

In August 2016,June 2017, we issued a promissory note to a non-relatedan unrelated third party in the amount of $150,000$12,500 bearing monthly interest at 10% annually. The note was due in one year from the execution and funding of the note. The loan is in default and in negotiation of settlement. At June 30, 2018, the accrued interest is $1,306.

·

During July 2017, we received a rateloan for a total of 2.5%$200,000 from an unrelated third party. The loan has been repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of June 30, 2018.  At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments. We recorded a gain on settlement of debt in other income for $20,927.

·

In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of June 30, 2018. The loan is in default and in negotiation of settlement. At June 30, 2018, the principal balance of the loan is $50,000.

·

In September 2017, we issued a promissory note to an unrelated third party in the amount of $51,000 with original issue discount of $8,500. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of June 30, 2018. The Company repaid $8,500 in cash in November 2017. In May 2018, the Noteholder received a total of 187,500,000 shares of our restricted stock with a fair value of $243,750 in satisfaction of the remaining balance of $42,500.  We recorded a loss on settlement of debt in other expense for $201,250 (See Note 6).

·

In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. The note is due in one year from the execution and funding of the note. The original issue discount is amortized over the term of the loan. Amortization for the original issuance discount for the six months ended June 30, 2018 was $3,000. At June 30, 2018, the principal balance of the loan net of discount is $29,500.

·

In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 100,0005,000,000 shares of our common stock. We recorded a debt discount in the amount of $800$3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid–in capital.  Amortization for the debt discount and original issuance discount were fully amortized as of June 30, 2018.  During April 2018, the Note was restated with principal balance of $60,000 including the original issuance discount of $10,000 due December 2018. In connection with this restated note, we issued 5,000,000 shares of our common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid–in capital.  Amortization for the debt discount and original issuance discount was $3,616 and $4,617, respectively for the six months ended June 30, 2018. As of June 30, 2018, the principal balance of the loan net of discount is $49,105.

·

In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid–in capital.  The debt discounts were fully amortized as of June 30, 2018. The loan is in default and in negotiation of settlement. At June 30, 2018, the principal balance of the loan net of discount is $60,000.

·

In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid–in capital. The debt discounts were fully amortized as of June 30, 2018. The loan is in default and in negotiation of settlement. At June 30, 2018, the principal balance of the loan net of discount is $120,000.

·

In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our common stock (See Note 6). We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-inpaid–in capital. The discount wasdebt discounts were fully amortized as of SeptemberJune 30, 2017. Amortization for the debt discount for the nine-months ended September 30, 2017 was $200. During March 2017, we issued a total of 50,000 restricted shares due to the default on repayment. The shares were valued at a fair value of $275 (See Note 6). During April 2017, the Notes with accrued interest were restated. The restated principal balance of $180,250 bears interest at 12% annually and is due October 20, 2017. In connection with this restated note, we issued 500,000 shares of our common stock. We recorded a debt discount in the amount of $2,417 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The discount was fully amortized as of September 30, 2017.  Amortization for the debt discount for the nine-months ended September 30, 2017 was $2,417.2018. The loan is in default and in negotiation of settlement. During November 2017, we issued a totalAt June 30, 2018, the principal balance of 250,000 restricted shares due to the default on repayment (See Note 10). At September 30, 2017, the accrued interestloan net of discount is $24,635.

$18,000.

·

On September 26, 2016,In December 2017, we issued a promissory note to a non-relatedan unrelated third party in the amount of $75,000 bearing interest at 10% annually.$60,000 with original issuance discount of $10,000. The note is due in one year from the execution and funding of the note. The loandiscount is in default and in negotiation of settlement. During October 2017, we issued a total of 100,000 restricted shares due to the default on repayment (See Note 10). At September 30, 2017, the accrued interest is $7,708.

·

In October 2016, we issued a promissory note to a non-related party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 600,000 shares of our common stock. We recorded a debt discount in the amount of $4,330 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $4,330 was fully amortized as of September 30, 2017.  Amortization for the debt discount for the nine-months ended September 30, 2017 was $2,165. At September 30, 2017, the accrued interest is $12,000. During March 2017, we issued a total of 350,000 restricted shares due to the default on repayment. The shares were valued at a fair value of $1,645 (See Note 6).

13

·

During November 2016, we received a loan for a total of $150,000 from a non-related party. The loan is repaid through scheduled payments through June 2018 along with interest on average 15% annum. We have recorded loan costs in the amount of $7,875 for the loan origination fees paid at inception date. The total loan cost of $7,875 is fully amortized over the term of the loan.  Amortization for the nine-monthsoriginal issuance discount for the six months ended SeptemberJune 30, 20172018 was $7,219.$5,000. At July 24, 2017,June 30, 2018, the principal balance of the loan was repaid in full. The interest expensenet of discount is $55,400. During August 2018, the Note holder sold the debt of $60,000 to a non–related party for the nine-months ended September 30, 2017 is $16,134.$50,000 (See Note 9).

(3)

At June 30, 2018, the balance of $1,920,846 net of discount of $124,588, consisted of the following convertible loans:

·

On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non–related parties. During the year ended December 31, 2015, we recorded the first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014.  The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. The loan is in default and in negotiation of settlement. At June 30, 2018, these convertible notes payable, at fair value, was recorded at $284.

·

During December 2015, our President and CEO, Mr. Deitsch, assigned $80,000 of his outstanding loan to a non-relatedan unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as the promissory note upon maturity date. On June 27, 2017, the Company owed principal balance of $80,000 plus accrued interest of $4,971. The total of $84,971 was assigned and sold to a non-relatedan unrelated third party in the form of a Convertible Redeemable Note (See Note 6(3)6(2)).

·

In April 2017, we issued a Convertible Promissory Note for $33,000 to a non-related party. The note carries interest at 12% annually and are due January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our Common Stock for the fifteen trading days preceding the conversion date. At September 30, 2017, the principal balance is $33,000 with accrued interest of $1,779.

·

In June 2017, we issued a promissory note to a non-related party in the amount of $12,500 bearing interest at 10% annually. The note is due in one year from the execution and funding of the note. In the event of our failure to pay the Note in a timely fashion, the Noteholder would receive 100,000 shares restricted, common stock on the date that is 10 business days after the maturity date.  At September 30, 2017, the accrued interest is $351.

·

During July 2017, we received a loan for a total of $200,000 from a non-related party. The loan is repaid through scheduled payments through January 2019 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The total loan cost of $5,500 is amortized over the term of the loan.  Amortization for the nine-months ended September 30, 2017 was $1,095.  At September 30, 2017, repayment of $8,671 was made. The interest expense for the nine-months ended September 30, 2017 is $10,965. At September 30, 2017, the principal balance of the loan net of discount is $186,954.

·

In July 2017, we issued a promissory note to a non-related party in the amount of $50,000 with original issuance discount of $10,000. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 2,000,000 shares of our common stock (See Note 6). We recorded a debt discount in the amount of $4,912 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The discount is amortized over the term of the loan.  Amortization for the debt discount and original issuance discount for the nine-months ended September 30, 2017 was $2,050 and $4,170, respectively. At September 30, 2017, the principal balance of the loan net of discount is $41,308.

·

In September 2017, we issued a promissory note to a non-related party in the amount of $51,000 with original issuance discount of $8,500. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 4,000,000 shares of our common stock (See Note 6). We recorded a debt discount in the amount of $3,656 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The discount is amortized over the term of the loan.  Amortization for the debt discount and original issuance discount for the nine-months ended September 30, 2017 was $610 and $1,420, respectively. At September 30, 2017, the principal balance of the loan net of discount is $40,874.

·

In September 2017, we issued a promissory note to a non-related party in the amount of $36,000 with original issuance discount of $6,000. The note is due in one year from the execution and funding of the note. The original issuance discount is amortized over the term of the loan. Amortization for the original issuance discount for the nine-months ended September 30, 2017 was $500 At September 30, 2017, the principal balance of the loan net of discount is $30,500.

(3)

At September 30, 2017, the balance of $1,431,861 consisted of the following convertible loans:

·

On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. During the year ended December 31, 2015, we recorded the first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014.  The notes carry interest at 8% and are due on March 19, 2018.  The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. At September 30, 2017, these convertible notes payable, at fair value, was recorded at $1,132.

14

·

On March 3, 2016, we issued a “Back-end Note” in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The Note was funded on September 8, 2016. The note carries interest at 8% and iswas due on March 3,September 21, 2017, unless previously converted into shares of restricted common stock. CoventryThe Noteholder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a fifty-fivefifty–five percent (55%) of average of the three lowest closing bid prices of our Common Stock for the twenty trading days preceding  the conversion date including the date of receipt of conversion notice. During MarchJuly and MayAugust 2017, the NoteholderNote holder made conversions of our common stocks satisfying the principal balance of $55,325. During February 2018, the Note holder made conversions of a total of 47,011,483109,876,500 shares of the company’s restrictedour common stock satisfying the Note in full with a fair value of $214,795 (See Note 6).

$156,625 in satisfaction of the remaining principal balance of $29,646.

·

On March 31, 2017, we issued anothera convertible denture in the amount of $80,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 8% and iswas due on March 30, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a fifty-fivefifty–five percent (55%) of the of the lowest closing bid price of our Common Stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. In connectionDuring February 2018, the Noteholder made a conversion of 70,123,500 shares of our restricted stock with the issuancea fair value of $294,885 in satisfaction of the Note of $30,854 (See Note 6).

The noteholder sold and assigned the remaining balance of $49,146 with accrued interest of $3,276 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five prior trading days including the conversion date. During April and May 2018, the Note holder made conversions of a total of 65,885,713 shares of our common stock with a fair value of $156,590 in satisfaction of the remaining principal balance of $49,146 (See Note 6).

·

On July 18, 2017, we issued a convertible denture in the amount of $150,000 to Coventry Enterprises, LLC (“Coventry”). The note payable, we recordedcarries interest at 8% and is due on July 18, 2018, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a day-one derivative lossfifty–five percent (55%) of $108,021.the of the lowest closing bid price of our Common Stock for the twenty trading days preceding the conversion date including the date of receipt of conversion notice. During February 2018, the noteholder sold and assigned the balance of $150,000 with accrued interest of $6,000 to an unrelated third party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The noteholder has the right to convert the note into shares of our Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five prior trading days including the conversion date. During May and June 2018, the Noteholder made conversions of a total of 120,891,284 shares of our restricted stock with a fair value of $202,292 in satisfaction of the Note of $70,000 (See Note 6).  At SeptemberJune 30, 2017,2018, the convertible note payable, at fair value, was recorded at $181,867. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend the Company another $80,000.

On September 30, 2017, in connection with the issuance of a convertible note of $80,000, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $3,623 using the Black-Scholes method on September 30, 2017. The warrants expire on March 30, 2020 (See Note 7).

·

During April 2016, we entered into a loan agreement with Greentree Financial Group, Inc. (“Greentree”) in connection with a bridge financing transaction, consisting of certain unsecured convertible promissory notes in principal amount up to $250,000, the first tranche of $50,000 was funded during April 2016 and matures one year from the funding of the Note. The conversion price is lower of $0.10 per share or 60% of the average of the three lowest volume weighted average prices for the ten consecutive trading days immediately prior to but not including the conversion date. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $39,089. During November 2016, the Noteholder made a conversion of 5,274,262 shares of our restricted stock satisfying the Note of $25,000 with a fair value of $44,008. During January and April 2017, the Noteholder made conversions of 8,248,721 shares of the company’s restricted stock satisfying the remaining Note of $25,000 and accrued interest in full with a fair value of $52,808(See Note 6). In addition, Greentree received 2,955,950 shares of our restricted stock with a fair value of $14,189. It was recorded as a loss on settlement of debt in other expenses

$204,425.

·

On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. OneThe $60,000 of the three convertible notes for $40,000 was issued to Greentree, and the other two convertible notes payable for a totalNotes were paid in full as of $80,000 were issued to B+A in April 2016.

December 31, 2017. The $40,000 Note to Greentree bears annual interest rateremaining balance of 12% and conversion price is the lower of $0.10 per share or 60% of the average of the three lowest volume weighted average prices for the ten consecutive trading days immediately prior to but not including the conversion date. In October 2016, Greentree made conversions of a total of 8,603,469 shares satisfying the note payable and accrued interest in full.

The $80,000$20,000 Notes to B+A bear annual interest rate of 10% and conversion price is equal to 60%55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. InAt June and July 2017, B+A made conversions of a total of 45,759,901 shares satisfying the Note of $39,376 with a fair value of $67,469 (See Note 6). At September 30, 2017,2018, the convertible notes payable, at fair value, waswere recorded at $87,067. In October 2017, a conversion of portion of the Note was made (See Note 9).$49,041. The loan is in default and in negotiation of settlement.

·

During June 2016, we issued a Convertible Debenture in the amount of $72,000 to a non-relatedan unrelated third party as a result of debt sale. The Note carries interest at 8% and iswas due on June 20, 2017, unless previously converted into shares of restricted common stock. The convertible note’s holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at fifty-fivefifty–five percent (55%) of the average of the three lowest VWAP prices of our Common Stock for the fifteen trading days preceding the conversion date. At SeptemberJune 30, 2017,2018, the convertible notes payable, at fair value, was recorded at $163,813. The loan is$214,522. During August 2018, a Note holder received a total of 300,000,000 shares of our restricted stock in default andsatisfaction of the principal balance of $72,000 with accrued interest in negotiation of settlement.

15full for a Note originated in July 2016 (See Note 9).

·

During June 2016, the notes payable of $50,000 originated in January 2016 with accrued interest of $4,800 was assigned and sold to a non-relatedan unrelated third party in the form of a Convertible Redeemable Note (See Note 5(2)). The note carries interest at 8% and iswas due on June 16, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at fifty-fivefifty–five percent (55%) of the average of the three lowest VWAP prices of our Common Stock for the fifteen trading days preceding  the conversion date. At September 30, 2017,During May 2018, the Note holder made a conversions of 228,000,000 shares of our restricted stock with a fair value of $319,200 in satisfaction of the principal balance of $54,800 at fair value, was recorded at $124,965. The loan is in default and in negotiation of settlement.

full (See Note 6).

·

During July 2016, we issued a convertible note to a non-relatedan unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0%. The note holder has the right to convert the notes into shares of Common Stock and convertible at a price of $0.05. The note is due in six months from the execution and funding of the note. In connection with the issuance of this note, we issued 300,000 shares of our common stock (See Note 6). We recorded a debt discount in the amount of $2,345 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized. The remaining discount of $1,345 was amortized during the nine-months ended September 30, 2017. The interest expense for the year ended September 30, 2017 is $5,667. On January 26, 2017, the principal and accrued interest was $56,567. During January 2017, 300,000 shares restricted, common stock were issued due to default on repayment (See Note 7).

$0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 iswas due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 were restated. The loanrestated principal balance of $65,600 bears monthly interest at a rate of 2.5% and is under personal guarantee by our President and CEO, Rik Deitsch.due August 14, 2018. In connection with the issuance of this restated note, we issued 300,0001,000,000 shares of our common stock (See Note 6). We have recorded a debt discount in the amount of $2,413$4,035 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-inpaid–in capital. The discount of $2,413 was fully amortized during the nine-months ended September 30, 2017. During August 2017, the accrued interest of $8,909 was paid in full and the Note was restated with the same principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 is due on February 2, 2018 and convertible at $0.05 per share. In connection with the restatement of this note, we issued 300,000 shares of our common stock (See Note 6). We have recorded a debt discount in the amount of $417 to reflect the value of the common stock. The debt discount was fully amortized during the nine-months ended Septemberas of June 30, 2017.2018. The loan is under personal guarantee by our President and CEO, Rik Deitsch. At SeptemberJune 30, 2017,2018, the convertible note payable, at fair value, was recorded at $6,085.

$4,165. The accrued interest as of June 30, 2018 is $7,490.

·

In FebruaryApril 2017, we issued a Convertible Promissory Note for $53,000$33,000 to a non-relatedan unrelated third party. The note carries interest at 12% annually and are due November 12, 2017.January 30, 2018. The Holder has the right to convert the loan, beginning on the date which is one hundred eighty (180) days following the date of the Note, into common stock at a price of sixty percent (60%) of the average of the three lowest trading prices of our Common Stock for the fifteen trading days preceding the conversion date. During August 2017, the Noteholder made the conversions of a total of 85,491,054 of our restricted stock satisfying the principal balance and accrued interest in fullof $16,040. During June 2018, the Note holder made a conversion of 150,000,000 shares of our restricted stock with a fair value of $90,976.

·

During August 2016, wesigned a Secured & Collateralized Convertible Promissory Note for $52,500 to LG Capital Funding, LLC (“LG”). The note carries interest at 8% and is due on August 22, 2017, unless previously converted into shares of restricted common stock. LG has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a price of  sixty percent (60%)$180,000 in satisfaction of the average of the two lowest trading prices of our Common Stock for the fifteen trading days preceding  the conversion date. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $52,500. During February and March 2017, LG made the conversions of a total of 20,971,375 of our restricted stock satisfying the principal balance and accrued interest in full with a fair value of $94,857.

The Back-end Note was funded during March 2017. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $38,404. During August 2017, LG made the conversions of a total of 106,713,358 of our restricted stock satisfying the principal balance and accrued interest in full with a fair value of $96,261.

During February 2017, wesigned a Secured & Collateralized Convertible Promissory Note for $52,500 to LG Capital Funding, LLC (“LG”). The note carries interest at 8% and is due on February 1, 2018, unless previously converted into shares of restricted common stock. LG has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a price of  sixty percent (60%) of the average of the two lowest trading prices of the Company’s Common Stock for the fifteen trading days preceding  the conversion date. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $52,500. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $38,374. During May and June 2017, LG made the conversions of a total of 43,244,572 of our restricted stock satisfying the principal balance and accrued interest in full with a fair value of $106,000.

16

·

During August 2016, we issued a Convertible Debenture to a non-related party in the amount of $51,000. The note carries interest at 12% and matures on May 19, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the average of the three lowest trading prices of our Common Stock for the twenty trading days preceding the conversion date. During February and March 2017, the Note holder made the conversions of a total of 19,573,258 of our restricted stock satisfying the principal balance and accrued interest in full with a fair value of $98,147.

·

During August 2016, we issued a Convertible Debenture to a non-related party in principal amount up to $225,000, the first tranche of $45,000 was funded during August 2016 and matures one year from the funding of the Note. The note carries interest at 6%. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the average of the three lowest trading prices of our Common Stock for the twenty trading days preceding  the conversion date. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $37,932. We have recorded loan costs in the amount of $4,500 for the loan origination fees paid at inception date. The total loan cost of $4,500 was amortized over the term of the loan.  At September 30, 2017, the loan cost was fully amortized. Amortization for the nine-months ended September 30, 2017 was $3,000. During March through May, 2017, the Note holder made conversions of a total of 25,558,744 shares of stock satisfying the principal balance and accrued interest in full for a fair value of $198,451.

·

The second tranche of $22,500 was funded during December 2016. We recorded loan costs in the amount of $2,250 for the loan origination fees paid at inception date. The total loan cost of $2,250 was fully amortized over the term of the loan.  Amortization for the nine-months ended September 30, 2017 was $2,250. During June and July 2017, the Note holder made conversions of a total of 31,582,547 shares of stock satisfying the principal balance and accrued interest in full for a fair value of $53,979.

·

During September 2016, the notes payable of $10,000 originated in December 2015 with accrued interest of $1,951 was assigned and sold to a non-related party in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on September 21, 2017, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest closing bid prices of our Common Stock for the twenty trading days preceding  the conversion date including the date of receipt of conversion notice. During May 2017, the Note holder exercised conversion to 5,432,195 shares of stock satisfying the note in full for a fair value of $26,412

·

During December, 2016, we issued a Convertible Debenture in the amount of $66,500 to Labrys Fund, LP (“Labrys”). The note carries interest at 12% and is due on June 6, 2017, unless previously converted into shares of restricted common stock. Labrys has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our Common Stock for the twenty trading days preceding  the conversion date. We issued 4,532,810 shares of common stock (the “Returnable Shares”) to Labrys as a commitment fee, provided, however, the Returnable Shares must be returned to our treasury if Labry elects to convert, prior to the date which is one hundred eighty (180) days following the Issue Date, all or any part of the outstanding and unpaid principal amount or interest of this Note into shares of Common Stock. In March 2017, the amendment was signed to waive Labry to return the Commitment Shares back to our treasury (See Note 6). We have recorded a debt discount of $49,861 for the fair value of stock issued on the inception date.  The loan is in default. The total loan cost of $49,861 was amortized over the term of the loan.  The loan cost was fully amortized as of September 30, 2017. Amortization for the nine-months ended September 30, 2017 was $44,478. During April through July 2017, the Note holder made conversions of a total of 138,541,668 shares of stock satisfying theremaining principal balance of $66,500 and default penalty of $22,617 in full for a fair value of $218,353$16,960 (See Note 6).

·

During MarchMay and October 2017, we issued another Convertible Debenture in the amountfor a total of $66,500$90,000 to Labrys. The note carries interest at 12% and is due on September 10, 2017, unless previously converted into shares of restricted common stock. Labrys has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our Common Stock for the twenty trading days preceding  the conversion date. In connection with the issuance of the convertible note payable, the Company encountered a day-one derivative loss of $67,987. During July through September 2017, the Note holder made conversions of a total of 163,760,392 shares of stock satisfying the principal balance of $46,461 and accrued interest for a fair value of $210,956 (See Note 6). At September 30, 2017, the convertible note payable, at fair value, was recorded at $55,642. During October 2017, conversions were made to satisfy the remaining balance of the Note.

During May 2017, we issued another Convertible Debenture in the amount of $45,000 to Labrys. The note carries interest at 12% and is due on November 3, 2017, unless previously converted into shares of restricted common stock. Labrys has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our Common Stock for the twenty-fivetwenty–five trading days preceding  the conversion date. In connection withDuring 2017, the issuanceNote holder made a conversion satisfying the principal balance of $11,057 and accrued interest. During February 2018, we issued 45,000,000 shares of our restricted stock to Labrys in settlement of the convertible note payable, the Company encountered a day-one derivative loss of $47,393. At September 30, 2017, the convertible note payable, at fair value, was recorded at $100,492. The loan isremaining balance in default and negotiation of settlement.

17

full (See Note 6).

·

During December 2016, we issued a Convertible Debenture to a non-relatedan unrelated third party in the amount of $110,000. The note carries interest at 12% and matures on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our Common Stock for the twenty five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest. During February 2018, the remaining balance of $46,999 with accrued interest forof $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note.  In connection with the settlement of the debt, we issued 70,621,469 shares of our common stock to the original Note holder with a fair value of $298,575.$125,000.

The new note of $49,819 carries interest at 8% and is due on February 13, 2019, unless previously converted into shares of restricted common stock. The Noteholder has the right to convert the note into shares of our Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five prior trading days including the conversion date. At SeptemberJune 30, 2017,2018, the convertible note payable, at fair value, was recorded at $105,905.

·

During December 2016, we issued a Convertible Debenture to a non-related party in the amount of $67,500. The note carries interest at 12% and matures on December 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of the Company’s Common Stock for the twenty five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 222,707,390 shares of stock satisfying the principal balance and accrued interest in full for a fair value of $304,050. (See Note 6).

·

During December 2016, we issueda Secured & Collateralized Convertible Debenture to a non-related party in the amount of $50,000. The note carries interest at 8% and matures on December 23, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our Common Stock for the twenty trading days including the conversion date. During June and July 2017, the Note holder made conversions of a total of 116,386,891 shares of stock satisfying the principal balance and accrued interest in full for a fair value of $123,121.

·

During January 2017, we issued a Convertible Debenture in the amount of $40,000 to a non-related party. The note carries interest at 8% and is due on January 17, 2018, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price sixty percent of the lowest closing bid price of our Common Stock for the twenty prior trading days including the conversion date. In connection with the issuance of the convertible note payable, the Company encountered a day-one derivative loss of $30,925. In July 2017, the company repaid the principal balance, accrued interest and prepayment penalty of the Note in full.

$118,379.

·

During May 2017, we issued a Convertible Debenture in the amount of $64,000 to a non-relatedan unrelated third party. The note carries interest at 8% and is due on May 4, 2018, unless previously converted into shares of restricted common stock. LabrysThe Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our Common Stock for the twenty trading days preceding  the conversion date. In connectionDuring November 2017, the Note holder made a conversion of our common stocks satisfying the principal balance of $856. During the six months ended June 30, 2018, the remaining balance of $63,144 with the issuanceaccrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted stock with a fair value of $70,938 in satisfaction of the convertible note payable,balance of $40,536 (See Note 6). At June 30, 2018, the Company encountered a day-one derivative lossremaining balance of $47,762. At September 30, 2017, the convertible note payable,$35,050, at fair value, was recorded at $144,891.

$81,785.   

·

During December 2015, our PresidentJanuary through June 2018, we issued convertible notes payable to the ten unrelated third parties for a total of $313,650 with original issue discount of $29,650. The notes are due in six months from the execution and CEO, Mr. Deitsch, assigned $80,000funding of his outstanding loaneach note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0005 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes, resulted in a non-related partybeneficial conversion feature in the formamount of a Convertible Redeemable Note. The note carries interest at 4% and was due on December 7, 2016. The Note reverted back as$235,913. In addition, upon the promissory note upon maturity date. On June 27, 2017,issuance of convertible notes, the Company owedissued 1,250,000 shares of common stock (See note 6). The Company has

recorded a debt discount in the amount of $3,087 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid–in capital. The total discount of $239,000 and original issuance discount of $29,650 was amortized over the term of the debt.  Amortization for the six months ended June 30, 2018 was $144,062. At June 30, 2018, the principal balance of $80,000 plus accrued interestthe loan, net of $4,971. The totaldiscount of $84,971 was assigned and sold to$124,588, is $189,062.

·

During February 2018, we issued a non-related partyconvertible denture in the formamount of a Convertible Redeemable Note (See Note 6(2)).$200,000 to an unrelated party. The note carries interest at 8% and is due on September 21, 2017,in February 2019, unless previously converted into shares of restricted common stock. The NoteholderNote holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at fifty-fivesixty percent (55%) of the lowest closing bid pricestrading price of our Common Stock for the twenty five trading days preceding  the conversion date including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, the Company encounteredwe recorded a day-oneday–one derivative loss of $75,006. During July and August 2017, the Note holder made conversions of a total of 164,935,000 shares of stock satisfying the principal balance of $55,325 for a fair value of $225,143. (See Note 6).$1,646,242. At SeptemberJune 30, 2017,2018, the convertible note payable, at fair value, was recorded at $73,365.$475,407. The note carries additional $200,000 “Back–end Note” ($100,000 each) with the same terms as the original note.

·

During April 2018, $65,000 of the $100,000 Back–end Note was funded. The note carries interest at 8% and is due in February 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day–one derivative loss of $100,700. At June 30, 2018, the convertible note payable, at fair value, was recorded at $154,507.

·

During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated party. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day–one derivative loss of $48,418. At June 30, 2018, the convertible note payable, at fair value, was recorded at $142,896. The note carries an additional “Back–end Note” with the same terms as the original note that enables the lender to lend to us another $60,000.

·

During June 2018, the $60,000 Back–end Note was funded. The note carries interest at 8% and is due in March 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day–one derivative loss of $68,067. At June 30, 2018, the convertible note payable, at fair value, was recorded at $142,896.

·

During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated party. The note carries interest at 8% and is due in May 2019, unless previously converted into shares of restricted common stock. The Note holder has the right to convert the note, until is no longer outstanding  into shares of Common Stock at sixty percent of the lowest trading price of our Common Stock for the twenty five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day–one derivative loss of $59,257. At June 30, 2018, the convertible note payable, at fair value, was recorded at $143,477.

In the evaluation of these financing arrangements, weThe Company has concluded that thesethe embedded conversion option and several other features did not meetembedded in the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, ithybrid debt agreement requires bifurcation and liability classification as liabilities, at fair value. We also concluded thatAs an alternative to this accounting, the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.

WeCompany elected to account for theserecord the entire hybrid contractsfinancing instrument as a single financial liability and measured at fair value under the guidance of ASC 815-15-25-4.  The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.

The holders of these convertible notes have substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with

18

the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.

Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of our Company, dividend distribution or spin off, dilutive issuances of our stock, etc. If the lender receives additional shares of our commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the existing shareholders. Such dilution would likely result in a significant drop in the per share price of our common stock. The potential dilutive nature of this note presents a very high degree of risk to us and our shareholders.SFAS155.

6.     STOCKHOLDERS' DEFICIT

Authorized Shares

On March 7, 2018, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 2,000,000,000 to 8,000,000,000.

Common Stock Issued for Serviceswith Indebtedness

DuringIn January and February 2017, we signed an agreement with a consultant to provide investor relation services for twelve months. In2018, in connection with the agreement, 1,500,000 shares of our restricted common stock were issued. The shares were valued at $0.0075 per share. We recorded an equity compensation charge of $7,256 during the nine-months ended September 30, 2017. The remaining unrecognized compensation cost of $3,994 related to non-vested equity-based compensation will be recognized over the remaining vesting and service period.

During January 2017,four notes payable, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 1,000,000 shares of our restricted common stock were issued. The shares were valued at $0.0087 per share. We recorded an equity compensation charge of $6,138 during the nine-months ended September 30, 2017. The remaining unrecognized compensation cost of $2,562 related to non-vested equity-based compensation will be recognized over the remaining vesting and service period.

During November 2016, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, a total of 3,000,000 shares of our restricted common stock were issued. The shares were valued at $0.012 per share. We recorded an equity compensation charge of $26,055 and $9,945 during the nine-months ended September 30, 2017 and the year ended December 31, 2016.

During July 2016, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement,issued a total of 4,250,000 shares of our restricted common stock were issued. Thewith a fair value of $9,887 (See Note 5).

In April 2018, in connection with a notes payable, we issued a total of 5,000,000 shares were valued at $0.0084 per share. We recorded an equity compensation charge of $17,801 and $17,899 during the nine-months ended September 30, 2017 and the year ended December 31, 2016.our common stock with a fair value of $8,678 (See Note 5).

Common Stock Issued for Conversion of Debt

During July 2016, we signed agreements withFebruary 2018, the Note holder made conversions of a consultant to provide investor relation services for twelve months. In connection with the agreement, 500,000total of 70,123,500 shares of our restricted common stock were issued. The shares were valued at $0.0084 per share. We recordedwith a fair value of $294,885 in satisfaction of the principal balance of $30,854 of an equity compensation charge of $2,094 and $2,156 during the nine-months ended September 30,$80,000 Note originated in March 2017 and the year ended December 31, 2016.(See Note 5).

During July 2016, we signed agreements withFebruary 2018, a consultant to provide investor relation services for six months. In connection with the agreement, 1,200,000Note holder received 109,876,500 shares of our restricted common stock were issued. The shares were valued at $0.0084 per share. We recordedwith a fair value of $156,625 upon conversion of $29,646 of an equity compensation charge of $2,499 and $7,581 during the nine-months ended September 30,$84,971 Note originated in June 2017 and the year ended December 31, 2016.(See Note 5).

During July 2016, we signed agreementsFebruary 2018, a Note holder received 45,000,000 of our restricted stock with a consultant to provide investor relation services for twelve months. In connectionfair value of $3,618,244 upon conversion of the remaining balance of $78,943 of $90,000 Notes originated in May and October 2017 (See Note 5).

During April and May 2018, a Note holder made conversions of a total of 65,885,713 shares of our common stock with a fair value of $156,590 in satisfaction of the agreement, 500,000remaining principal balance of $49,146 assigned and purchased from a Note originated in March 2017 (See Note 5).

During May and June 2018, a Note holder made conversions of a total of 120,891,284 shares of our restricted common stock were issued. The shares were valued at $0.0084 per share. We recorded an equity compensation chargewith a fair value of $2,094$202,292 in satisfaction of the balance of $70,000 of a $156,000 Note assigned and $2,156 during the nine-months ended September 30,purchased from a Note originated in July 2017 and the year ended December 31, 2016.(See Note 5).

During July 2016, we signed an agreement withMay 2018, a consultant to provide investor relation services for twelve months. In connection with the agreement,Note holder received a total of 625,000187,500,000 shares of our restricted stock with a fair value of 243,750 in satisfaction of the remaining balance of $42,500 from a Note originated in September 2017  (See Note 5).

During May 2018, a Note holder received a total of 228,000,000 shares of our restricted stock with a fair value of $319,200 in satisfaction of the remaining principal balance of $54,800 assigned and purchased from a Note originated in June 2016 (See Note 5).

During June 2018, a Note holder made a conversion of 150,000,000 shares of our restricted stock with a fair value of $180,000 in satisfaction of the remaining principal balance of $16,960 of $33,000 Notes originated in May 2017 (See Note 5).

During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted stock with a fair value of $70,938 in satisfaction of the principal balance of $34,060 and accrued interest of $6,476 assigned and purchased from a Note originated in May 2017 (See Note 5).

Common Stock Issued for Settlement of Default Penalty

During February, 2018, in connection with the settlement of a default penalty of debt, we issued 70,621,469 shares of our common stock were issued. The shares were valued at $0.009 per share. We recorded an equity compensation chargewith a fair value of $3,082 and $2,543 during$125,000 to the nine-months ended September 30, 2017 and the year ended December 31, 2016.Note holder (See Note 5).

Common Stock Issued for Debt Modification

During April 2017,2018, we issued a total of 350,0001,000,000 restricted shares to a Note holder due to the default on repayment of the promissory note of $50,000 originated in October 20162017 (See Note 5). The shares were valued at fair value of $1,645.

19

During March 2017, we issued a total of 50,000 restricted shares to a Note holder due to the default on repayment of the convertible note of $150,000 originated in August 2016 (See Note 5). The shares were valued at fair value of $275.

In March 2017, the amendment was signed to waive Labrys’ obligation to return the 4,532,810 Returnable Shares issued as a commitment fee (See Note 5).

During January 2017, we issued a total of 300,000 restricted shares to a Note holder due to the default on repayment of the convertible note of $50,000 originated in July 2016 (See Note 5). The shares were valued at fair value of $2,520.

Common Stock Issued with Indebtedness

In January 2017, in connection with the restatement of a convertible note payable of $56,567, we issued 300,000 shares of our common stock with a fair value of $2,413 (See Note 5).

In April 2017, in connection with the restatement of a promissory note payable of $180,250, we issued 500,000 shares of our common stock with a fair value of $2,413 (See Note 5).

During April 2017, 1,000,000 warrants were exercised via cashless exercise into 615,230 shares with a fair value of $3,015 (See Note 7).

In July 2017, in connection with the issuance of a promissory note payable of $50,000, we issued 2,000,000 shares of our common stock with a fair value of $4,912 (See Note 5).

In August 2017, in connection with the restatement of a promissory note payable of $56,567, we issued 300,000 shares of our common stock with a fair value of $417 (See Note 5).

In September 2017, in connection with the issuance of a promissory note payable of $51,000, we issued 4,000,000 shares of our common stock with a fair value of $3,656 (See Note 5).$1,700.

Common Stock Issued for Conversion of DebtServices

During July and August 2017,June 2018, the Company signed an agreement with a Note holder received 164,935,000consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of ourcompany’s restricted stock withcommon stocks were issued. The share was valued at $0.0012 per share. The Company recorded an equity compensation charge of $10,000 during the six months ended June 30, 2018. The remaining unrecognized compensation cost of $110,000 related to non–vested equity–based compensation to be recognized by the Company over the remaining vesting period.

Beneficial Conversion Features

During January through June 2018, the Company has recorded a beneficial conversion feature in the amount of $235,913 as an additional paid in capital due to the difference between the conversion price and the fair value of $225,143 upon conversionthe Company’s common stock on the date of $55,325issuance of an $84,971 Note originated in June 2017(See Notethe convertible notes (See note 5).

7.     STOCK OPTIONS AND WARRANTS

Common Stock Warrants

On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $3,625 using the Black-Scholes method on September 30, 2017. The warrants expire on March 30, 2020 (See Note 5).

On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $1,765 using the Black-Scholes method at September 30, 2017. The warrants expire on March 3, 2021.

On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants were valued at their fair value of $1,330 using the Black-Scholes method at September 30, 2017. The warrants expire on April 4, 2019.

During July 2015, we issued a total of 4,400,000 shares of our restricted stock and 4,400,000 warrants to settle outstanding commissions’ payable in aggregate of $59,000 with TCN. The shares were valued at $0.185 per share and the warrants were valued at $0.1009 per share. The warrants expired on June 30, 2016. During October, 2016, warrants were re-priced from exercise prices from $0.20 per share to an exercise price of $0.05 per share, the warrants expired on March 31, 2017.

During October, 2016, we repriced 19,685,000 from exercise prices from $0.20 per share to an exercise price of $0.05 per share, the warrants expired on March 31, 2017.

During March 2016, we issued 916,667 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expired on March 31, 2017.

During April 2015, we issued a total of 1,000,000 two year warrants to the notes holders to purchase common stock at an exercise price of $0.35 per share. During April 2017, 1,000,000 warrants were exercised via cashless exercise into 615,230 shares with a fair value of $3,015 (See Note 6).

A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the nine-monthssix months ended SeptemberJune 30, 2017:2018:

23

The following table summarizes information about fixed-pricefixed–price warrants outstanding as of SeptemberJune 30, 20172018:

At SeptemberJune 30, 2017,2018, the aggregate intrinsic value of all stock options and warrants outstanding and expected to vest was $0. The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is “in-the-money”“in–the–money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-moneyin–the–money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0008,$0.0014, closing stock price of our common stock on SeptemberJune 29, 2017.2018. There were no in-the-moneyin–the–money warrants at SeptemberJune 30, 2017.2018.

9.8.     COMMITMENTS AND CONTINGENCIES

Operating Leases

In February 2013, we entered into a three-yearthree–year operating lease for monthly payments of approximately $3,500 which expired in January 2016. In February 2016, we entered into a new three-yearthree–year operating lease for monthly payments of approximately $3,200 which expires in February 2019.  ReceptoPharm leases a lab and renewed its operating lease agreement for five years in July of 2012. The lease requires monthly payments of approximately $6,400 from August 1, 2012 through August 1, 2017. The lease was renewed in February 2016 for another five years beginning August 1, 2017.

Future minimum payments under these lease agreements are as follows:

Rent expense for the three-monthsthree–months ended SeptemberJune 30, 2018 and 2017 was $34,574 and 2016 approximated $31,867 and $28,736,$31,227, respectively. Rent expense for the nine-monthssix–months ended SeptemberJune 30, 2018 and 2017 was $67,802 and 2016 approximated $92,552 and $87,280,$60,685, respectively.  

Consulting Agreements

During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. The shares and note payable have not been issued as of SeptemberJune 30, 2017.2018. We have accrued the $142,500 in accrued expense and equity compensation.

Litigation

Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc.

On June 1, 2015, ReceptoPharm entered into a settlement agreement with Patricia Meding, a former officer and shareholder of ReceptoPharm.  The settlement relates to a lawsuit filed by Ms. Meding against ReceptoPharm (Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06, New York Supreme Court, Queens County) in which she claimed to own certain shares of ReceptoPharm stock and claimed to be owed amounts on a series of promissory notes allegedly executed in 2001 and 2002.

The settlement agreement executed on June 1, 2015 provides that ReceptoPharm will pay Ms. Meding a total of $360,000 over 35 months. The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter. To date, ReceptoPharm has made all monthly payments due under the agreement.  In the event of default on any of the payments due under the settlement agreement, the settlement amount would increase by an additional $200,000.  As of SeptemberJune 30, 2017, we2018, all payments were made and the settlement is concluded. We have accruedrecorded $200,000 in other income for the legal settlement amount at present valueover accrual of $67,282 and an additional contingency of $200,000. The settlement agreement is personally guaranteed by Rik Deitsch, our CEO.default upon payments in full in April 2018.

24

Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch 

On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants inLiquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik “Rik” Deitsch,, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562.2011–CV–199562. Liquid Packaging Resources, Inc. (“LPR”) claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees.

Mr. Deitsch and Nutra Pharma Corp. then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE.11–CV–01663–ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. Mr. Deitsch and Nutra Pharma Corp.  moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). Mr. Deitsch and Nutra Pharma Corp. believe the suit is without merit.

After September 30, 2011, atAt LPR's request, the parties mediated the dispute before LPR responded to the Motion to Dismiss.dispute. At the mediation, the parties worked out an agreement whereby Nutra Pharma Corp. would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $350,000 payable over a 7 month periodmonths in equal $50,000 amounts. This agreement was reached by us because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation, which would likely be substantial and not recouped. While Nutra Pharma Corp.  had counterclaims we could assert, we believe this was a practical resolution. The settlement allowed us to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of our stock valued at $400,000 at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011.  We madeFollowing several payments under the August, September and November payments (totaling $150,000) in a timely fashion. We were late forparties’ agreement, the parties entered into two amended payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $5,000 towards that payment. At December 31, 2011,schedules as accommodations to Nutra Pharma Corp. had made total payments of $205,000 with an additional $150,000 owed. In order to allow us to skip the December payment, LPR agreed to another accommodation whereby we would pay both the December and January payment with an additional $10,000 on or before January 16, 2012. We were unableit to make thispayments that had been missed.  Nutra Pharma Corp. did not make a payment in March 2012 and on January 26, 2012 signed an amended payment schedule adding an additional $15,000 for a total of $175,000 owed. Our CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $25,000 was paid in January, with subsequent payments of $30,000 due monthly on the 15th of March through the 15th of July, 2012. We failed to make the March payment and wasLPR subsequently called Nutra Pharma Corp. in default of the Agreement. Under the original agreement, if we are in default of the agreement, LPR has the right to sell shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 representing the new total cash amount due to LPR by us.parties’ agreement.

On June 11, 2012, LPR sold theirits debt to Southridge Partners, LLP in an agreement to be paid out over time. In August 2013, LPR cancelled their agreement with Southridge Partners, LLP.  As of September 30, 2017, LPR continues to hold the collateral stock. We are currently negotiating a settlement with LPR. Upon the settlement of the outstanding debt, LPR will return the collateral shares to us.

Involuntary Petition of Bankruptcy

On August 31, 2012, certain former ReceptoPharm employees and a former ReceptoPharm consultant filed a Petition for Involuntary Bankruptcynotice of intent to administratively dissolve in May 2015 (with the dissolution becoming effective in December 2015) and has not pursued its claimed default against us in the United States Bankruptcy Court, Southern District of Florida. The Petitioners originally claimed they were owed $990,927 from Nutra Pharma Corp. in the form of accrued wages and promissory notes, but amended their claim to $816,662 in a subsequent filing. In response to the Petition, we filed a motion to dismiss the action. On September 30, 2013, the Company entered into a settlement agreement with the Petitioners and the bankruptcy action was dismissed. In full and final satisfaction of all claims, the settlement agreement provides for payment to the Petitioners of a total sum of $350,000. As of September 30, 2017, $35,000 has been paid. As set forth below, the Petitioners have now filed a complaint in the 17^th Judicial Circuit in and for Broward County, Florida to recover amounts allegedly owing to them under the settlement agreement.any court or other formal proceeding since that date.

Paul Reid et al. v. Nutra Pharma Corp. et al.

On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17^th17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover amounts$315,000 allegedly owing to them under thea settlement agreement reached in thean involuntary bankruptcy action referenced above.that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms.  On September 28, 2016, Nutra Pharma and Receptopharm filed a motion to dismiss the lawsuit. That motion is currently pending.

Nutra Pharma and Receptopharm believe that the lawsuit is without merit and also intend to file a counterclaim against these former employees/consultants for misconduct that Nutra Pharma discovered after execution of the aforementioned settlement agreement.  We intend to vigorously contest this matter.

25

During December 2015,On October 26, 2017, the Petitioner'sCourt dismissed the claims and accruals for a totalunpaid wages/breach of $1,085,468 that have passedwritten debt confirms but allowed the statuteclaim for alleged breach of limitation were written off, included in the amount was the accrued salary of $815,747, officer’s loan and accrued interest for $129,466, salary and payroll tax payable of $140,255.settlement agreement to go forward.  Since the Petitioners can only reinforce the settlement amount due to passing of statute of limitation, we have accrued the settlement for $315,000 and recorded the gain on settlement of $770,968 in other income for the year ended December 31, 2015. The accrued balance for the settlement has not changed as of SeptemberJune 30, 2017.2018.

10.9.     SUBSEQUENT EVENTS

Common Stock Issued for Conversion of Debt Conversions

During October 2017, LabryJuly 2018, a Note holder made conversions of a conversiontotal of 86,049,33293,595,964 shares of our restricted stock satisfyingin satisfaction of the remainingbalance of $50,000 of a $156,000 Note assigned and purchased from a Note originated in July 2017.

During August 2018, a Note holder received a total of 300,000,000 shares of our restricted stock in satisfaction of the principal balance of $25,039$72,000 with accrued interest in full for thea Note of $66,500 originated in March 2017July 2016 (See Note 5).

Settlement of Note Payable

During October 2017, B+A madeAugust 2018, a conversionNote holder sold the debt of 42,365,263 shares of stock satisfying $19,416 of the principal balance for the Note of $80,000$60,000 originated in April 2016December 2017 to a non–related party for $50,000 (See Note 5).

Common Stock Issued for Debt ModificationAccount Payable

During October and November 2017, weAugust 2018, the Company issued a total of 350,0002,800,000 shares of the company’s restricted shares duestock to settle the default on repayment (See Note 5)outstanding fees of $4,200 with a vendor.

Series A Preferred StockConvertible Notes Payable

Effective October 30, 2017, pursuantDuring July 2018, we issued a convertible denture in the amount of $50,000 to authorityan unrelated party. The note carries interest at 8% and is due in July 2019, unless previously converted into shares of its Boardrestricted common stock. The Note holder has the right to convert the note into shares of Directors, filed a CertificateCommon Stock. Conversion price is equal to 55% of Determination for its Series A Preferred Stock. The Series A Preferred Stock consiststhe average of 3,000,000 shares. The Series A Preferred Stock will vote with the Corporation’s common stock as a single class on all matters or consentsthree lowest volume weighted average prices for the Corporation’s common stockholders. Each share of Series A Preferred Stock is entitledfifteen consecutive trading days immediately prior to one thousand votes per share.including the conversion date.

The Series A Preferred Stock was issued to Rik J. Deitsch, the Corporation’s Chairman, to discharge four hundred thousand dollars ($400,000) of Mr. Deitsch’s loan to the Corporation. Upon issuance of the Series A Preferred Stock Mr. Deitsch will own 62.7% of the Corporation’s voting stock.

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introduction

Our business during the thirdsecond quarter of 20172018 has focused upon marketing our homeopathic drugs for the treatment of pain:

·

Nyloxin®Nyloxin^® (Stage 2 Pain)

·

Nyloxin®Nyloxin^® Extra Strength (Stage 3 Pain)

·

Pet Pain–Away™

We will continue this focus during the remainder of 2017.2018.

During our thirdsecond quarter of 20172018 and thereafter, the following has occurred:

On August 3, 2017April 10, 2018 we announced that the textbook, Multimodal Management of Canine Osteoarthritis, Second Edition, includes referenceswe had filed a new provisional patent to protect our intellectual property surrounding the development of cobra venom–based products for treating pain in dogs.a drug to treat Amyotrophic Lateral Sclerosis (ALS or “Lou Gehrig’s Disease”). The additionnew drug entity relies on the predicate research on our existing drug, RPI–78M with modification specific to the treatment of our researchALS.

On April 19, 2018 we announced that we have partnered with NxGen Brands, LLC; a company specializing in the new textbook on canine arthritis further supports the usesales and marketing of Pet Pain–Away among Veterinarians as an alternativeinnovative healthcare products and service solutions, to opiatesmarket and NSAIDS.distribute Nyloxin^® through their various distribution platforms.

On October 17, 2017June 28, 2018 we published to our websiteannounced that we had signed a definitive Letter of Intent for a $4 Million financing that will fund a subsidiary joint venture. JAH Neal Holdings LLC will act as the minority Joint Venture (JV) partner with a 49% stake in the subsidiary for their $4 million investment. Nutra Pharma will maintain a 51% stake in the venture and will contribute an exclusive license for all of our Over–the–Counter (OTC) products, were featured inwhich currently includes: Nyloxin®, Pet Pain–Away™ and Luxury Feet. The stakeholders will jointly manage the JV.

On July 3, 2018 we announced that DEG Productions had signed an interview aired October 16 onexclusive distribution deal with one of the Spanish language show: ALTO NIVEL TV with Leida Alvarez (https://youtu.be/EtMmtWWqlXs)nation’s leading direct mail marketers to launch a private label version of Pet Pain–Away™. The interview was conducted by Leida Alvarezproduct will be marketed nationally to a proven list of pet product buyers through a stand–alone custom mailer. The direct mail campaign is complimentary to the ongoing television campaign in that it is designed to acquire new customers and convert them into the monthly auto–ship program.  

On July 17, 2018 we announced that we had executed an agreement with filming at our laboratory facilityAmerican Marketing Technologies (“AMT”) to launch an integrated Internet marketing campaign combined with a program to target a number of national retail chains. AMT’s approach to market the products is to create more awareness through social media and online marketing while trying to have these products available on shelves across the reptile farm that houses our cobras for venom production.country. As they build brand awareness online; they will provide the pull–through to put the products on store shelves throughout the US.

Nyloxin^®/Nyloxin^® Extra Strength

We offer Nyloxin^®/Nyloxin^® Extra Strength as our over–the–counter (OTC) pain reliever that has been clinically proven to treat moderate to severe (Stage 2) chronic pain.

Nyloxin^® and Nyloxin^® Extra Strength are available as a two ounce topical gel for treating joint pain and pain associated with arthritis and repetitive stress, and as a one ounce oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain. Both the topical gel and oral spray are packaged and sold as a one–month supply.

Nyloxin^® and Nyloxin^® Extra Strength offer several benefits as a pain reliever. With increasing concern about consumers using opioid and acetaminophen–based pain relievers, the Nyloxin^® products provide an alternative that does not rely on opiates or non–steroidal anti–inflammatory drugs, otherwise known as NSAIDs, for their pain relieving effects. Nyloxin^® also has a well–defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API) of Nyloxin^®, Asian cobra venom, has been studied in more than 46 human clinical studies. The data from these studies provide clinical evidence that cobra venom provides an effective treatment for pain with few side effects and has the following benefits:

·

safe and effective;

·

all natural;

·

long–acting;

·

easy to use;

·

non–narcotic;

·

non–addictive; and

·

analgesic and anti–inflammatory.

Potential side effects from the use of Nyloxin^® are rare, but may include headache, nausea, vomiting, sore throat, allergic rhinitis and coughing.

The primary difference between Nyloxin^® and Nyloxin^® Extra Strength is the dilution level of the venom. The approximate dilution levels for Nyloxin^® and Nyloxin^® Extra Strength are as follows:

Nyloxin^®

·

Topical Gel: 30 mcg/mL

·

Oral Spray: 70 mcg/mL

Nyloxin^® Extra Strength

·

Topical Gel: 60 mcg/mL

·

Oral Spray: 140 mcg/mL

27

In December 2009,2011, we began marketing Nyloxin^® and Nyloxin^® Extra Strength at www.nyloxin.com. Both Nyloxin^® and Nyloxin^®Extra Strength are packaged in a roll–on container, squeeze bottle and as an oral spray. Additionally, Nyloxin^® topical gel is available in an 8 ounce pump bottle.

In December of 2013, we announced an agreement with MyNyloxin.com for the exclusive rights to market and distribute Nyloxin^® in the Network Marketing channel. MyNyloxin.com provides a business opportunity to their Distributors to earn commissions on the sale of our products through their Distributor groups. In January of 2014, we announced the first product shipments to the MyNyloxin Independent Entrepreneurs (MIEs). MyNyloxin conducts webinars, conference calls and live meetings to support recruitment of new MIEs as well as to provide product and business education. In April of 2014, we announced that MyNyloxin.com had signed an agreement that creates the MyNyloxin Telemarketing Division (MTD). MTD began their telemarketing campaign on April 7 to identify customers for Nyloxin^® as well as potential Distributors for MyNyloxin.com. In June of 2014, we announced that MyNyloxin had begun rolling out a national television campaign to support Nyloxin^® branding and sales. In November of 2014, MyNyloxin.com changed their name to Lumaxa.

In early 2017, we created a new website for Nyloxin^® and brought online sales back in–house (www.nyloxin.com).

We are currently marketing Nyloxin^® and Nyloxin^® Extra Strength as treatments for moderate to severe chronic pain. Nyloxin^® is available as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress. Nyloxin^® Extra Strength is available as an oral spray and gel application for treating the same physical indications, but is aimed at treating the most severe (Stage 3) pain that inhibits one’s ability to function fully.

Nyloxin^® Military Strength

In December 2012, we announced the availability of Nyloxin^® Military Strength for sale to the United States Military and Veteran's Administration. Over the past few years, the U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications, particularly opiates. In 2009, close to 3.8 million prescriptions for pain relievers were written in the military. This staggering number was more than a 400% increase from the number of prescriptions written in the military in 2001. But prescription drugs are not the only issue. The most common and seemingly harmless way to treat pain is with non non–steroidal, anti–inflammatory drugs (NSAIDS). But there are risks. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction and life–threatening allergic reactions can occur. It is reported that approximately 7,600 people in America die from NSAID use and some 78,000 are hospitalized. Ibuprofen, also an NSAID has been of particular concern in the military. The terms “Ranger Candy” and “Military Candy” refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain. But when taking anti–inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake. Our goal is that with Nyloxin^®, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military. The Nyloxin^®Military Strength represents the strongest version of Nyloxin^® available and is approximately twice as strong as Nyloxin^® Extra Strength. We are working with outside consultants to register Nyloxin^® Military Strength and the other Nyloxin^® products for sale to the US government and the various arms of the military as well as the Veteran's Administration. To date, we have been unable to get our products onto the Federal Supply Schedule for eventual sales to governmental agencies or to the US Military, but will continue these efforts.

International Sales

We are pursuing international drug registrations in Canada, Mexico, India, Australia, New Zealand, Central and South America and Europe. Since European rules for homeopathic drugs are different than the rules in the US, we cannot estimate when this process will be completed. On March 25, 2013 we announced the publication of our patent and trademark for Nyloxin^® in India.  We are currently working with potential Distributors in India. In February, 2015 we completed the first test shipments to India. We plan to begin active sales and marketing in India over the next several quarters.